Cargando…
Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug
A fundamental issue related to therapy of HIV-1 infection is the emergence of viral mutations which severely limits the long term efficiency of the HIV-protease (HIV-PR) inhibitors. Development of new drugs is therefore continuously needed. Chemoinformatics enables to design and discover novel molec...
Autores principales: | Jayaswal, Amit, Mishra, Ankita, Mishra, Hirdyesh, Shah, Kavita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Biomedical Informatics
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070054/ https://www.ncbi.nlm.nih.gov/pubmed/24966525 http://dx.doi.org/10.6026/97320630010227 |
Ejemplares similares
-
Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment
por: Dallas, Shannon, et al.
Publicado: (2013) -
Virtual Screening of Indonesian Herbal Database as HIV-1 Protease Inhibitor
por: Yanuar, Arry, et al.
Publicado: (2014) -
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
por: Wiesmann, Frank, et al.
Publicado: (2011) -
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines
por: Bandiera, Elisabetta, et al.
Publicado: (2016) -
Identification of mutation resistance coldspots for targeting the SARS‐CoV2 main protease
por: Krishnamoorthy, Navaneethakrishnan, et al.
Publicado: (2021)